Kumar S Nishanth, Lankalapalli Ravi S, Kumar B S Dileep
Agroprocessing and Natural Products Division, National Institute for Interdisciplinary Science and Technology (NIIST), Council of Scientific and Industrial Research (CSIR), Thiruvananthapuram, Kerala, 695019, India,
Appl Biochem Biotechnol. 2014 May;173(1):116-28. doi: 10.1007/s12010-014-0808-3. Epub 2014 Mar 13.
The in vitro synergistic antibacterial activity of six proline-based cyclic dipeptides [cyclo(D-Pro-L-Leu), cyclo(L-Pro-L-Met), cyclo(D-Pro-L-Phe), cyclo(L-Pro-L-Phe), cyclo(L-Pro-L-Tyr), and cyclo(L-Pro-D-Tyr)] in combination imipenem and ceftazidime was investigated in the present manuscript. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of the cyclic dipeptides were compared with those of the standard antibiotics (imipenem and ceftazidime). The synergistic antibacterial activities of cyclic dipeptides with imipenem or ceftazidime were assessed using the checkerboard and time-kill methods. The results of the present study showed that the combined effect of six cyclic dipeptides with imipenem predominantly recorded synergistic interaction (FIC index <0.5), whereas combination of certain cyclic dipeptides with ceftazidime recorded additive. The time-kill curve showed that the growth of the test bacteria was completely attenuated after 12-24 h of treatment with a 50:50 ratio of proline-based cyclic dipeptides and antibiotics. These synergistic effects have a potential role in delaying the development of resistance as the antibacterial activity is achieved with the very low concentrations of cyclic dipeptides and antibiotics. The cytotoxicity of cyclic dipeptides was tested against VERO cell line (African green monkey kidney cell line), and no cytotoxicity was recorded for cyclic dipeptides up to 100 μg/mL. These findings suggest that combination of cyclic dipeptides and antibiotics might be a good strategy for the individualization of novel templates for the development of new antimicrobial agents or combinations of drugs for antimicrobial chemotherapy. Moreover, these combinations may lead to the development of a new and vital antimicrobial combination against the infections caused by pathogenic bacteria. The in vitro synergistic activity of cyclic dipeptides with antibiotics against medically important bacteria is reported here for the first time.
在本论文中,研究了六种脯氨酸基环二肽[环(D-脯氨酸-L-亮氨酸)、环(L-脯氨酸-L-蛋氨酸)、环(D-脯氨酸-L-苯丙氨酸)、环(L-脯氨酸-L-苯丙氨酸)、环(L-脯氨酸-L-酪氨酸)和环(L-脯氨酸-D-酪氨酸)]与亚胺培南和头孢他啶联合使用时的体外协同抗菌活性。将环二肽的最低抑菌浓度(MIC)和最低杀菌浓度(MBC)与标准抗生素(亚胺培南和头孢他啶)的进行比较。使用棋盘法和时间杀菌法评估环二肽与亚胺培南或头孢他啶的协同抗菌活性。本研究结果表明,六种环二肽与亚胺培南联合使用时,主要表现为协同相互作用(FIC指数<0.5),而某些环二肽与头孢他啶联合使用时表现为相加作用。时间杀菌曲线表明,在用脯氨酸基环二肽和抗生素以50:50的比例处理12-24小时后,测试细菌的生长完全受到抑制。由于在极低浓度的环二肽和抗生素下就能实现抗菌活性,这些协同作用在延缓耐药性发展方面具有潜在作用。测试了环二肽对VERO细胞系(非洲绿猴肾细胞系)的细胞毒性,在高达100μg/mL的环二肽浓度下未记录到细胞毒性。这些发现表明,环二肽与抗生素联合使用可能是开发新型抗菌剂或抗菌化疗药物组合新模板个体化的良好策略。此外,这些组合可能会导致开发出一种针对病原菌引起感染的新型且重要的抗菌组合。本文首次报道了环二肽与抗生素对医学上重要细菌的体外协同活性。